The association between chronic obstructive pulmonary disease and Parkinson's disease: A nationwide population-based retrospective cohort study

QJM: An International Journal of Medicine

Volumn 108, Issue 1, 2015, Pages 39-45

  Li, C H ^a,b   Chen, W C ^a,b   Liao, W C ^a,c   Tu, C Y ^a,d,e   Lin, C L ^a,b   Sung, F C ^a,b   Chen, C H ^a,b,c   Hsu, W H ^a,d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c Graduate Institute of Clinical Medical Science   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TAIWAN; AGE DISTRIBUTION; COMPLICATION; INCIDENCE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEX RATIO; VERY ELDERLY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PARKINSON DISEASE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; TAIWAN;

EID: 84928678793     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcu136     Document Type: Article

References (34)

1. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J 2010; 35:913-22.
2. Villeneuve S, Pepin V, Rahayel S, Bertrand JA, de Lorimier M, Rizk A, et al. Mild cognitive impairment in moderate to severe COPD: a preliminary study. Chest 2012; 142:1516-23.
3. Rusanen M, Ngandu T, Laatikainen T, Tuomilehto J, Soininen H, Kivipelto M. Chronic obstructive pulmonary disease and asthma and the risk of mild cognitive impairment and dementia: a population based CAIDE study. Curr Alzheimer Res 2013; 10:549-55.
4. Zhang Z, Yan J, Chang Y, ShiDu Yan S, Shi H. Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr Med Chem 2011; 18:4335-43.
5. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the ''common'' neurologic disorders? Neurology 2007; 68:326-37.
6. Davie CA. A review of Parkinson's disease. Br Med Bull 2008; 86:109-27.
7. Fujita K, Nakabeppu Y, Noda M. Therapeutic effects of hydrogen in animal models of Parkinson's disease. Parkinson's Dis 2011; 2011:307875.
8. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011; 26(Suppl. 1):S1-58.
9. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012; 72:893-901.
10. Cheng T-M. Taiwan's National Health Insurance system:high value for the dollar. In: Okma K.G.H., Crivelli L., eds, Six Countries, Six Reform Models: The Health Reform Experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan. New Jersey: World Scientific, 2009:71-204.
11. Shen TC, Lin CL, Chen CH, Tu CY, Hsia TC, Shih CM, et al. Increased risk of chronic obstructive pulmonary disease in patients with rheumatoid arthritis: a population-based cohort study. QJM: Mon J Assoc Phys 2014; 107:537-43.
12. Shen TC, Lin CL, Chen CH, Tu CY, Hsia TC, Shih CM, et al. Increased risk of chronic obstructive pulmonary disease in patients with systemic lupus erythematosus: a populationbased cohort study. PLoS One 2014; 9:e91821.
13. Shen TC, Chung WS, Lin CL, Wei CC, Chen CH, Chen HJ, et al. Does chronic obstructive pulmonary disease with or without Type 2 diabetes mellitus influence the risk of lung cancer? Result from a population-based Cohort Study. PLoS One 2014; 9:e98290.
14. Eisner MD, Blanc PD, Yelin EH, Sidney S, Katz PP, Ackerson L, et al. COPD as a systemic disease: impact on physical functional limitations. Am J Med 2008; 121:789-96.
15. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:367-70; discussion 71-2.
16. Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J Chronic Obstructive Pulmonary Dis 2011; 6:199-208.
17. Garvey JF, Taylor CT, McNicholas WT. Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J 2009; 33:1195-205.
18. Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, Byrne A, et al. An intact canonical NF-kappaB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol 2011; 186:1091-6.
19. Antonelli Incalzi R, Marra C, Giordano A, Calcagni ML, Cappa A, Basso S, et al. Cognitive impairment in chronic obstructive pulmonary disease-a neuropsychological and spect study. J Neurol 2003; 250:325-32.
20. Ortapamuk H, Naldoken S. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. Ann Nuclear Med 2006; 20:99-106.
21. de la Torre JC. Critical threshold cerebral hypoperfusion causes Alzheimer's disease? Acta Neuropathologica 1999; 98:1-8.
22. Liu B, Gao HM, Hong JS. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 2003; 111:1065-73.
23. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinson Related Disord 2004; 10(Suppl. 1):S3-7.
24. McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson's disease. Advances Neurol 2001; 86:83-9.
25. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scandinavica 1999; 100:34-41.
26. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008; 167:90-5.
27. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006; 70:1469-80.
28. Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, et al. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineinduced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem 2009; 284:29065-76.
29. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 1991; 56:1441-4.
30. To M, Yamamura S, Akashi K, Charron CE, Barnes PJ, Ito K. Defect of adaptation to hypoxia in patients with COPD due to reduction of histone deacetylase 7. Chest 2012; 141:1233-42.
31. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112:1821-30.
32. Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson's disease in Denmark. Diab Care 2011; 34:1102-8.
33. Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diab Care 2008; 31:2003-5.
34. Palacios N, Gao X, McCullough ML, Jacobs EJ, Patel AV, Mayo T, et al. Obesity, diabetes, and risk of Parkinson's disease. Mov Dis: Off J Mov Dis Soc 2011; 26:2253-9.